Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Citado por Google
Similares en SciELO
Similares en Google
Compartir
Revista Colombiana de Ciencias Químico - Farmacéuticas
versión impresa ISSN 0034-7418versión On-line ISSN 1909-6356
Resumen
VALLEJOS NARVAEZ, Álvaro et al. Characterization of patients prescribed losartan in doses higher than the maximum daily dose: Their problems and intervention. Rev. colomb. cienc. quim. farm. [online]. 2022, vol.51, n.2, pp.912-924. Epub 21-Dic-2023. ISSN 0034-7418. https://doi.org/10.15446/rcciquifa.v51n2.105566.
Introduction:
Hypertension is one of the most prevalent diseases in our country. Type II angiotensin receptor antagonists are one of the most common treatments; however, its maximum effective dose is controversial.
Aim:
The objective of study to characterize a population of a health promoting entity in Colombia, which received a dose of losartan greater than 100 mg/day for management of arterial hypertension.
Methodology:
The study included a prescription base of 3816 cases with arterial hypertension, in management with losartan potassium at doses higher than 100 mg/day, with a proportional sample of 300 cases; in whom a maximum dose alert (100 mg/day) was applied in prescription. Pharmacotherapeutic profile, drug interactions, dosage changes, and changes in blood pressure figures were described. To confirm therapeutic effect of losartan potassium in controlling blood pressure figures, statistical tests were performed (Tukey, Bonferroni).
Results:
Of the 300 patients, 224 (74.6%) had a blood pressure record at beginning of prescription of losartan potassium at 100 mg/day; after the intervention, a dose reduction was achieved in 70 cases (23.3%). 76 cases (25.3%) did not have any follow-up paraclinical.
Conclusion:
It was concluded that losartan potassium at doses greater than 100 mg/day did not show statistically significant differences for blood pressure control. We found insufficient clinical and scientific evidence to support the treatment with losartan more than 100 mg/day for hypertension in our population.
Palabras clave : Losartan; arterial hypertension; therapeutic; risk; hyperkalemia.